Search Results

Hudson Therapeutics announced that Shaperon, an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding with Dong-A ST for the development of nanobody-based new drugs.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara ® (Ustekinumab).

Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.

Electra Therapeutics, Inc. today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

NeuroBo Pharmaceuticals, Inc. (“NeuroBo”) (Nasdaq: NRBO), and Dong-A ST Co., Ltd. (“Dong-A”) (KOSE: A000640) today announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726.